Cornell dots show promise in targeting cancer cells during surgery
The U.S. Food and Drug Administration (FDA) has approved the first clinical trial of a new technology that uses radiolabeled nanoparticles to brighten cancer cells so they can be detected by a PET-optical imaging camera.
Researchers from Memorial Sloan-Kettering Cancer Center (MSKCC) and Cornell University are collaborating with Hybrid Silica Technologies, a Cornell start-up company, and Dutch optical imaging developer O2view on the project and clinical trial.
New Data Shows Decline in Medical Imaging Utilization
A new analysis of Medicare data finds that spending on medical imaging continues to decline and that Medicare patients are receiving fewer imaging procedures. Learn More
MITA Now Includes Radiopharmaceutical Industry in Membership
With new membership MITA unites both halves of nuclear medicine. Learn More
CT Lung Cancer Screening Named Top Five Advance in 2011
The American Society of Clinical Oncology (ASCO) named CT-based lung cancer screening amongst 2011’s top five advances in its annual report on progress against cancer. Learn More
- © 2012 National Electrical Manufacturers Association |
- Privacy Policy |
- Terms & Conditions